Fairvalue-Calculator Fairvalue-Calculator
EN DE

Biomark Diagnostics Inc (BMKDF) Fair Value & Analysis

Healthcare · US · Market cap $41.8M

Price$0.3917
Fair Value$0.0500
Upside-87.2%
Quality95/100
Evidence: Low Range $0.0400 – $0.0700

Fair value as of: Jun 24, 2026

Analysis

Biomark Diagnostics Inc (BMKDF) currently trades at $0.3917, while our model-based Fair Value estimate is $0.0500 — implying the stock looks roughly 87.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -34% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -54% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Biomark Diagnostics Inc (BMKDF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0500 versus a price of $0.3917 — about −87% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BMKDF?
Our 21-model fair value for Biomark Diagnostics Inc is $0.0500 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.3917.
What is the quality score of BMKDF?
Biomark Diagnostics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.